Sanara MedTech (SMTI)
NASDAQ:SMTI
Top Page
Sanara MedTech
(NASDAQ:SMTI)
Select Model
Select Model
Rating:46Neutral
Price Target:
$16.00
▼(-45.80% Downside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by weak profitability and a materially more levered balance sheet despite strong revenue growth and high gross margins. Technicals also reflect a clear downtrend. Offsetting these risks, the latest earnings call was constructive with reaffirmed growth guidance and improved operational metrics, including positive operating cash flow.
Positive Factors
Strong revenue growth and high gross margins
Sustained top-line expansion combined with exceptionally high gross margins indicates the core product economics are scalable. Durable high gross margins provide a stable cushion to fund sales expansion and R&D, enabling reinvestment without eroding unit profitability over multiple quarters.
Negative Factors
Sharply increased leverage and fragile equity base
A large jump in leverage and a thin/negative equity base materially raise financial risk. Persistent losses or higher rates could amplify interest expense, constrain liquidity, and limit strategic flexibility, making refinancing or covenant management a multi‑quarter structural risk to execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth and high gross margins
Sustained top-line expansion combined with exceptionally high gross margins indicates the core product economics are scalable. Durable high gross margins provide a stable cushion to fund sales expansion and R&D, enabling reinvestment without eroding unit profitability over multiple quarters.
Read all positive factors
Sanara MedTech (SMTI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$165.10M
Dividend YieldN/A
Average Volume (3M)61.65K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth30.55%
EPS Growth-340.19%
CountryUS
Employees141
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.13
Shares Outstanding9,167,040
10 Day Avg. Volume48,775
30 Day Avg. Volume61,645
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)33.96
Price to Sales (P/S)1.95
P/FCF Ratio93.17
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit2.01
Enterprise Value/Ebitda15.84
Forecast
1Y Price Target
$36.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.65
Revenue Forecast (FY)$118.60M
Sanara MedTech Business Overview & Revenue Model
Company Description
Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions des...
How the Company Makes Money
Sanara MedTech primarily makes money by selling wound-care and related medical products into healthcare providers and facilities. Revenue is generated through product sales (recognized when products are delivered/used per customer arrangements) ac...
Sanara MedTech Earnings Call Summary
Earnings Call Date:Mar 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Positive
The call highlights strong commercial momentum and meaningful financial improvement in 2025 — including record revenue, expanded gross margins, materially higher adjusted EBITDA, a positive operating cash flow turnaround, distributor and facility expansion, Vizient contract win, and clear R&D/IP progress. Near-term headwinds include a Q4 continuing-operations net loss, a noncash impairment charge, higher operating expenses driven by strategic investments, a sizable increase in long-term debt, and THP wind-down cash impacts. Management reiterated confident, externally provided guidance for 2026 and plans targeted investments (sales coverage expansion, R&D) to support growth. Overall, the positive operational and financial achievements, plus tangible growth catalysts, outweigh the listed challenges.Positive Updates
Record-Breaking Full Year Revenue
Net revenue of $103.1M for full year 2025, the first time above $100M, representing 19% year-over-year growth.
Negative Updates
Q4 Continuing Operations Net Loss and Operating Income Pressure
Q4 2025 net loss from continuing operations of $1.1M ($0.13 per diluted share) versus continuing operations net income of $0.9M ($0.10 per diluted share) in prior year; reported Q4 operating income declined to $1.1M from $2.3M year-over-year.
Read all updates
Q4-2025 Updates
Positive
Negative
Record-Breaking Full Year Revenue
Net revenue of $103.1M for full year 2025, the first time above $100M, representing 19% year-over-year growth.
Read all positive updates
Company Guidance
Sanara reaffirmed full‑year 2026 net revenue guidance of $116.0–$121.0 million (≈13–17% growth vs. 2025 net revenue of $103.1 million) and provided Q1 2026 revenue guidance of ~$26.7–$27.2 million (≈14–16% YoY growth). Management said it is comfortable with 2026 liquidity given $16.6 million of cash and $46.0 million of long‑term debt at 12/31/25, and expects operating cash flows to support planned investments (FY2025 cash from operations was $6.8 million, inclusive of ~ $9 million of THP‑related cash use); the THP wind‑down is substantially complete with no material future cash expectations. The company reiterated plans to invest in field sales (historically ~40 reps with targeted additions in Q1 2026) and R&D to drive the guided growth, and reminded modelers that employee commissions and annual bonuses are typically paid in Q1, increasing early‑year cash outlays.Sanara MedTech Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
22
Negative
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 103.12M | 86.67M | 64.99M | 45.84M | 24.14M |
| Gross Profit | 92.94M | 78.53M | 57.14M | 39.48M | 21.83M |
| EBITDA | 11.81M | -1.86M | -289.10K | -11.57M | -7.22M |
| Net Income | -37.56M | -9.66M | -4.30M | -7.94M | -7.92M |
Balance Sheet | |||||
| Total Assets | 72.94M | 88.09M | 73.87M | 61.04M | 36.40M |
| Cash, Cash Equivalents and Short-Term Investments | 16.58M | 15.88M | 5.15M | 8.96M | 18.65M |
| Total Debt | 48.19M | 32.29M | 11.79M | 819.22K | 425.44K |
| Total Liabilities | 67.01M | 49.18M | 29.28M | 19.32M | 6.24M |
| Stockholders Equity | 5.93M | 39.40M | 44.83M | 41.83M | 30.64M |
Cash Flow | |||||
| Free Cash Flow | 2.16M | -253.08K | -3.51M | -6.30M | -5.56M |
| Operating Cash Flow | 6.79M | -23.78K | -3.25M | -5.55M | -4.81M |
| Investing Cash Flow | -8.36M | -6.61M | -10.21M | -3.51M | -5.28M |
| Financing Cash Flow | -8.48M | 17.37M | 9.64M | -627.35K | 28.30M |
Sanara MedTech Technical Analysis
Negative
29.52
Price Trends
20.22
Negative
21.91
Negative
25.93
Negative
Market Momentum
-0.75
Positive
42.13
Neutral
23.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMTI, the sentiment is Negative. The current price of 29.52 is above the 20-day moving average (MA) of 19.22, above the 50-day MA of 20.22, and above the 200-day MA of 25.93, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 42.13 is Neutral, neither overbought nor oversold. The STOCH value of 23.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMTI.
Sanara MedTech Risk Analysis
Sanara MedTech disclosed 49 risk factors in its most recent earnings report. Sanara MedTech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sanara MedTech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $196.09M | 27.96 | 11.91% | ― | 6.23% | 283.88% | |
71 Outperform | $200.55M | 16.41 | 9.56% | 2.15% | -12.35% | -17.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $212.22M | -2.25 | -18.58% | ― | -43.95% | -620.21% | |
47 Neutral | $183.80M | -9.67 | -249.40% | ― | 19.61% | -3.42% | |
46 Neutral | $165.10M | -5.36 | -178.57% | ― | 30.55% | -340.19% |
* Healthcare Sector Average
SMTI
Sanara MedTech
18.01
-12.18
-40.34%
INFU
InfuSystem Holdings
9.70
4.23
77.33%
OSUR
Orasure Technologies
3.07
-0.36
-10.50%
STXS
Stereotaxis
1.89
0.09
5.00%
UTMD
Utah Medical Products
62.60
7.59
13.80%
STSS
Sharps Technology, Inc.
1.67
-11.02
-86.84%
Sanara MedTech Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Sanara MedTech Unveils 2026 Strategy in Investor Presentation
Neutral
Mar 2, 2026
Sanara MedTech Inc. has prepared a new investor presentation summarizing its priorities, strategy and anticipated revenue for the 2026 fiscal year, which it plans to use in meetings with investors and analysts, including at the TD Cowen 46th Annua...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.